What Is a GLP-1 Medication? A Plain-English Explainer

If you have heard friends, co-workers or half of your social feed talk about “GLP-1s,” you are not imagining it. These medications went from a niche diabetes treatment to one of the most discussed topics in medicine in just a few years. But the conversation online is noisy. Some posts make them sound like magic; others make them sound dangerous for everyone.

This guide cuts through that. It explains, in plain English, what a GLP-1 medication actually is, how it works in the body, what the major clinical trials found, what the common and serious side effects are, and who these drugs are and are not meant for. Everything here is drawn from official and peer-reviewed sources, which are listed at the end.

Important: This article is general education, not medical advice. Only a licensed clinician who knows your health history can tell you whether a GLP-1 medication is appropriate for you, and at what dose.

The short version

GLP-1 stands for glucagon-like peptide-1. It is a hormone your small intestine releases after you eat. A GLP-1 medication is a drug designed to act like that hormone, only much longer-lasting and stronger. In the body it:

• nudges the pancreas to release insulin when blood sugar is high,
• reduces the release of glucagon, a hormone that raises blood sugar,
• slows how quickly food leaves your stomach, and
• acts on areas of the brain involved in hunger and fullness.

The combined result, for most people, is that they feel satisfied with less food. That reduced intake is the main driver of weight loss. Researchers in the landmark STEP 1 trial put it directly: weight loss with semaglutide “stems from a reduction in energy intake owing to decreased appetite.”

Where GLP-1 comes from: the natural hormone

Your gut is not just a digestive tube; it is also a hormone factory. When food reaches the small intestine, specialized cells release several signaling hormones. GLP-1 is one of them. According to Cleveland Clinic’s overview, natural GLP-1 has four main jobs:

1. Triggering insulin release. Insulin moves sugar from the blood into cells. GLP-1 boosts insulin release mainly when glucose is elevated, which is why these drugs carry a relatively low risk of low blood sugar on their own.
2. Blocking glucagon. Glucagon tells the liver to release stored sugar. Less glucagon means less sugar pouring into the bloodstream after a meal.
3. Slowing stomach emptying. Food stays in the stomach longer, which flattens blood-sugar spikes and keeps you feeling full.
4. Increasing satiety. GLP-1 signals reach parts of the brain that process hunger and fullness.

The catch is that your own GLP-1 breaks down within minutes. That is why scientists developed drugs that resist breakdown and keep acting for a day, or for a whole week.

What “GLP-1 receptor agonist” means

You will often see these drugs called GLP-1 receptor agonists (or GLP-1 RAs). An “agonist” is a substance that attaches to a receptor on a cell and switches on the same response as the natural messenger. So a GLP-1 receptor agonist binds to GLP-1 receptors and produces GLP-1-like effects. Other names you may see include incretin mimetics and GLP-1 analogs.

There is also a newer category. Tirzepatide activates both the GLP-1 receptor and the receptor for another gut hormone called GIP (glucose-dependent insulinotropic polypeptide). That is why it is described as a dual GIP/GLP-1 receptor agonist. In everyday conversation, people lump it in with “GLP-1s,” and so do we on this site, while noting the difference where it matters.

And in 2026 the FDA approved orforglipron, a small-molecule GLP-1 receptor agonist taken as a daily pill. Unlike peptide drugs, the FDA’s announcement noted it “does not need to be taken on an empty stomach.”

The main GLP-1 medications, in one table

Below is a simplified overview of GLP-1-based medicines discussed most often in the US. Approvals change, so always check the current FDA label. For more detail, see our guide to which GLP-1s are FDA-approved for weight loss.

Active ingredient	Example brand names	How it’s taken	Main FDA-approved uses
Semaglutide	Ozempic, Rybelsus	Weekly injection / daily tablet	Type 2 diabetes (and heart-risk reduction for some products)
Semaglutide	Wegovy (injection and pill)	Weekly injection / daily tablet	Chronic weight management; heart-risk reduction
Tirzepatide	Mounjaro	Weekly injection	Type 2 diabetes
Tirzepatide	Zepbound	Weekly injection	Chronic weight management; obstructive sleep apnea in adults with obesity
Liraglutide	Victoza / Saxenda (and generics)	Daily injection	Type 2 diabetes / chronic weight management
Orforglipron	Foundayo	Daily tablet	Chronic weight management
Dulaglutide	Trulicity	Weekly injection	Type 2 diabetes

Notice something important: the same molecule can be sold under different names for different conditions at different doses. Ozempic and Wegovy both contain semaglutide, but they are separate products with separate labels. Using a diabetes product for weight loss is “off-label” use, which the NIH explains is something you should feel comfortable asking your clinician about.

How GLP-1 medications cause weight loss

1. Appetite and the brain

The biggest lever is the brain. GLP-1 receptors are found in regions that regulate appetite and food intake. NIDDK describes semaglutide and liraglutide as mimicking “a hormone called GLP-1 that targets areas of the brain that regulate appetite and food intake.” Many people describe this as quieter “food noise”: fewer intrusive thoughts about eating and less interest in large portions. That is a subjective description from patients, not a measured clinical endpoint, but it matches the measured reduction in energy intake.

2. Slower stomach emptying

Because food leaves the stomach more slowly, you feel full sooner and stay full longer. This is also a key reason for the most common side effects, like nausea and bloating, especially early on. We cover this in depth in GLP-1 nausea: why it happens and how to manage it.

3. Blood sugar effects

The insulin and glucagon effects matter most for people with type 2 diabetes, but they also help explain improvements in blood-sugar markers seen in trials of people without diabetes. In STEP 1, among participants with prediabetes at the start, 84.1% on semaglutide had normal blood sugar by week 68, compared with 47.8% on placebo.

For a deeper look at the biology, read how GLP-1 medications work for weight loss in our GLP-1 Guide hub.

What the major trials actually found

Social media is full of before-and-after claims. The more reliable picture comes from large, randomized, placebo-controlled trials. Two are especially important.

STEP 1 (semaglutide 2.4 mg weekly)

Published in the New England Journal of Medicine in 2021, STEP 1 enrolled 1,961 adults without diabetes who had a BMI of 30 or more (or 27 or more with a weight-related condition). Everyone also received lifestyle counseling, including a 500-calorie daily deficit and encouragement toward 150 minutes of weekly activity.

After 68 weeks:

• Average weight change was −14.9% with semaglutide versus −2.4% with placebo.
• 86.4% of the semaglutide group lost at least 5% of their starting weight, versus 31.5% on placebo.
• About half (50.5%) lost at least 15%, versus 4.9% on placebo.

SURMOUNT-1 (tirzepatide weekly)

Published in 2022, SURMOUNT-1 enrolled 2,539 adults without diabetes. After 72 weeks, average weight change was −15.0%, −19.5% and −20.9% at the 5 mg, 10 mg and 15 mg doses, compared with −3.1% on placebo.

How to read these numbers

Averages hide a wide range. Some participants lost much more; some lost very little. Trials also include structured lifestyle support that many real-world patients do not get. The 2025 joint advisory from four US nutrition and obesity societies summarized the evidence this way: GLP-1s reduce body weight by “5% to 18% in trials, with modestly lower effects in real-world analyses.”

The NIH also points out that most weight loss on medication happens in the first six months, and that losing even 5% to 10% of starting weight can lower blood sugar, blood pressure and triglycerides. You do not need dramatic results for meaningful health gains.

If you want to see the trial data mapped out over time, the GLP-1 weight-loss timeline tool are good next stops.

Who GLP-1 weight-loss medications are for

The NIH’s guidance on weight-management medications says a clinician may prescribe one if you are an adult with:

• a BMI of 30 or greater, or
• a BMI of 27 or greater plus a weight-related health problem such as high blood pressure or type 2 diabetes.

Some products, including semaglutide (Wegovy) and liraglutide (Saxenda), are also approved for certain adolescents aged 12 and older. You can check your BMI with our free BMI calculator, but remember that BMI is only a screening tool; your clinician will look at the whole picture.

NIDDK is also clear that these drugs are not for cosmetic weight loss: “never take a weight management medication only to improve the way you look.”

Who should not take them

The FDA labels for GLP-1 weight-management drugs share some important restrictions. They are not used in people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). NIH guidance also says weight-loss medications should not be used during pregnancy or when planning a pregnancy, and are not recommended while breastfeeding.

Other conditions, such as a history of pancreatitis, gallbladder disease, severe digestive problems, kidney disease or diabetic eye disease, require careful discussion with a clinician. This is one reason an honest, complete medical history matters before starting.

Side effects: what is common and what is serious

Common side effects

Digestive symptoms are by far the most common. In STEP 1, nausea was reported by 44.2% of people on semaglutide (versus 17.4% on placebo), diarrhea by 31.5%, vomiting by 24.8% and constipation by 23.4%. Most of these events were mild to moderate, temporary and resolved without stopping treatment. Still, 4.5% of the semaglutide group stopped treatment because of digestive side effects.

The joint nutrition advisory notes that these effects tend to appear in the first weeks and with each dose increase, then fade with a stable dose. That is why prescribers typically increase the dose gradually over several months.

Serious but less common risks

Cleveland Clinic lists rare but severe possible side effects including pancreatitis, acute kidney injury (often linked to dehydration from vomiting or diarrhea) and worsening diabetic retinopathy. Gallbladder problems such as gallstones were more frequent with semaglutide than placebo in STEP 1 (2.6% vs 1.2%), consistent with the known effects of rapid weight loss.

Rodent studies found thyroid C-cell tumors with some of these drugs, which is why the labels carry a boxed warning. It is not known whether this applies to humans, but it is the reason for the MTC and MEN 2 restriction above.

Muscle and nutrition

Weight lost on any diet includes some lean mass, and GLP-1 medications are no exception. In a body-composition subgroup of STEP 1, lean mass fell in absolute terms, although the proportion of lean mass relative to total body weight increased. The 2025 advisory recommends prioritizing protein and resistance training during treatment. Our guide to how much protein you need on a GLP-1 covers what the experts suggest.

GLP-1s are not a replacement for lifestyle habits

A recurring theme in every official source is that medication works best as part of a broader plan. NIDDK states plainly: “Medications don’t replace physical activity or healthy eating habits as a way to lose weight.” The trials themselves all paired the drug with diet and activity counseling.

In practice, that means:

• Protein-forward, smaller meals, especially while appetite is low.
• Resistance training at least two days a week to help protect muscle.
• Adequate fluids and fiber to reduce constipation and dehydration risk.
• Sleep and stress management, which the advisory lists as part of a full lifestyle assessment.

Our high-protein eating guide and first 30 days guide put these into practical steps.

What happens if you stop

Obesity is a chronic disease, and the NIH says you will “probably” regain some weight after stopping a weight-management medication. Keeping healthy eating and activity habits may reduce how much returns. This is not a reason to avoid treatment, but it is an important part of informed consent. Talk with your clinician about a long-term plan before you start, not after.

Brand-name, compounded and “research” products

Because demand has been so high, many unofficial versions have appeared. The FDA warns that compounded GLP-1s are not FDA-approved, meaning they have not been reviewed for safety, effectiveness or quality. The agency has received reports of dosing errors with compounded semaglutide, and it has warned companies selling semaglutide, tirzepatide and other compounds labeled “for research purposes” or “not for human consumption.” The FDA recommends getting a prescription from a licensed clinician and filling it at a state-licensed pharmacy.

FDA red flags to watch for include prices that seem too good to be true, no screening by a licensed clinician before a prescription, and products that arrive warm, damaged or without instructions.

How much do GLP-1s cost?

Prices have changed a lot, and they vary by product, dose and insurance. We track this in our GLP-1 cost guide and break down specifics in semaglutide cost without insurance.

Questions to bring to your clinician

If you are considering a GLP-1, these questions can make your appointment more productive:

1. Based on my health history, am I a candidate for an FDA-approved weight-management medication?
2. Which medication and form (injection or pill) fits my situation, and why?
3. What side effects should I expect, and which symptoms mean I should call you right away?
4. How will we handle dose increases if I have side effects?
5. How will we protect my muscle and nutrition while my appetite is low?
6. How long do you expect me to stay on treatment, and what is the plan if I stop?
7. What will it cost, and are there lower-cost options?

The bottom line

A GLP-1 medication mimics a natural gut hormone to help the body manage blood sugar and to reduce appetite. In large trials, FDA-approved GLP-1-based drugs produced average weight losses of roughly 15% to 21% over about a year and a half when combined with lifestyle support, far more than placebo. They also cause frequent digestive side effects, carry some serious but uncommon risks, and usually need to be continued to maintain results.

Used under medical supervision, they are a powerful tool. They are not a shortcut, and they are not right for everyone. Explore the rest of our GLP-1 Guide hub for the next steps, including eligibility, getting a prescription and what the first month looks like.

Medical disclaimer: Weightomics publishes general health information for education only. It is not a substitute for professional medical advice, diagnosis or treatment. Never start, stop or change a medication without talking to a licensed clinician.